PCM
KPTI icon

Prelude Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Prelude Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-133
Closed -$27K – 1805
2018
Q1 		$27K Buy
+133
New +$26.5K ﹤0.01% 1224

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Prelude Capital Management's KPTI Position: Q1 2026 in Review

Prelude Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 28,723 shares — an estimated $211K sold.

Prelude Capital Management first reported a position in KPTI in Q4 2016 and held it in 22 quarters. The position peaked at $360K in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Prelude Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 28,723 Karyopharm Therapeutics shares in Q1 2026, an estimated $211K.
  • Prelude Capital Management first reported a position in Karyopharm Therapeutics in Q4 2016 and held it in 22 quarters.
  • Prelude Capital Management's Karyopharm Therapeutics position peaked at $360K in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.